Celldex's hives drug faces safety questions despite Phase 3 successes

Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction following administration of the drug. The ...